Drug · CHEMBL74
CROMOLYN SODIUM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CROMOLYN SODIUM. Drugs and targets, record CHEMBL74. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL74
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Aerocrom, Allercrom, Aspire, Brol-eze, Catacrom, Clariteyes, Crolom, Cromogen, Cromogen e-breathe, Cromolux, Cromoptic, Cromosol, Cromosol optha, Cusilyn, Dominion pharma hayfever, Eye-crom, Gastrocrom, Glycavent, Gppe syncroner inha, Hay-crom, Intal, Intal 5, Lomudal, Lomusol, Murine, Nalcrom, Nasalcrom, Opticrom, Opticrom aq, Resiston one, Resiston treatment pack, Rynacrom, Rynacrom allergy, Rynacrom co, Steri-neb cromogen, Vivicrom, Vividrin, Viz-on
- ChEMBL
- Other names
- Astilyn, Cromoglicate sodium, Cromoglycic acid, Cromolyn disodium salt, Disodium cromolyn, FPL-670, FPL.670, NSC-109500, Natrii cromoglicas, Sodium cromoglicate, Sodium cromoglycate, Sodium cromolyn
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases16
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 16Source Open Targets
See all 16 diseasesTrials16
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02371941 | Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis | Phase 4 | 16 | 2023-10-26 | cromolyn sodium | Its name | ClinicalTrials.gov |
| NCT01933464 | An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema | Phase 1/2 | 10 | 2019-07-30 | cromolyn sodium | Its name | ClinicalTrials.gov |
| NCT04846348 | Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis | Phase 2 | 1 | 2024-04-25 | sodium cromolyn | Its name | ClinicalTrials.gov |
| NCT03864328 | A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF | Phase 2 | 108 | cromolyn sodium | Its name | ClinicalTrials.gov | |
| NCT07142291 | PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | Phase 2 | 105 | cromolyn sodium | Its name | ClinicalTrials.gov | |
| NCT05076682 | Reverse Triple Negative Immune Resistant Breast Cancer | Phase 2 | 90 | sodium cromoglicate | Its name | ClinicalTrials.gov | |
| NCT00745199 | Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus | Phase 2 | 62 | cromolyn sodium | Its name | ClinicalTrials.gov | |
| NCT02412020 | Treatment of Refractory Chronic Cough With PA101 | Phase 2 | 52 | sodium cromoglicate | Its name | ClinicalTrials.gov | |
| NCT07526558 | Mast Cell Treatment in Post-tick Bite Illness (PTBI) | Phase 2 | 50 | cromolyn sodium | Its name | ClinicalTrials.gov | |
| NCT06801626 | Novel Strategies for Reducing Burn Scar Itch | Phase 3 | 44 | cromolyn sodium | Its name | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oral Cromolyn vs Placebo: deaths from any cause | 0 of 9 | 0 of 7 | 16 | NCT02371941 | Trial comparisons |
| Oral Cromolyn vs Placebo: serious adverse events | 0 of 9 | 0 of 7 | 16 | NCT02371941 | Trial comparisons |
| Cromolyn vs Vehicle: serious adverse events | 0 of 5 | 0 of 5 | 10 | NCT01933464 | Trial comparisons |
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL74
GET https://conductscience.org/api/drugs/v1/CHEMBL74/targets